Engage Therapeutics Inc.   Report issue

For profit Phase 2
Founded: Summit NJ United States (2017)
Status: Acquired by UCB (2020)

Organization Overview

First Clinical Trial
2018
NCT03478982
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Engage Therapeutics Inc. | EngageTherapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

alprazolam (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Epilepsy (Phase 2)

Seizures (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1